In our study, we found that activation of AKT/mTOR pathway was related to poor survival in DLBCL patients treated with CHOP/CHOPE for 3-years and 5-years OS (P=0.033, P=0.028), and R-CHOP for 5-years OS (P=0.023), but not R-CHOP for 3-years OS (P=0.051). The gene discussed is AKT1; the disease is diffuse large B-cell lymphoma.